Business Update18 Jul 2024, 11:06 pm
Dr. Reddy’s Signs Non-Exclusive Patent Licensing Agreement with Takeda for Vonoprazan, a Novel Gastrointestinal Drug, in India
AI Summary
Dr. Reddy’s Laboratories Ltd. has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONO™ in two strengths, 10mg and 20mg. The agreement is part of Dr. Reddy’s continuous efforts to make innovative medicines available to patients in India through strategic collaborations.
Key Highlights
- Dr. Reddy’s has signed a non-exclusive patent licensing agreement with Takeda for Vonoprazan, a novel gastrointestinal drug.
- Vonoprazan is a potassium competitive acid blocker used to treat reflux esophagitis and other acid peptic disorders.
- Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONO™ in two strengths, 10mg and 20mg.
- The agreement is part of Dr. Reddy’s continuous efforts to make innovative medicines available to patients in India through strategic collaborations.
- Vonoprazan is proven to be effective and approved for the treatment of reflux esophagitis, gastric ulcer, duodenal ulcer, prevention of reoccurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration or NSAIDs administration.